 Connection
Joana Mack to Humans
This is a "connection" page, showing publications Joana Mack has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.286 |
|
|
|
-
Mack JM, Crary SE. How we approach coagulopathy with vascular anomalies. Pediatr Blood Cancer. 2022 08; 69 Suppl 3:e29353.
Score: 0.035
-
Mack JM, Peterson EC, Crary SE, Moran JH, Neville K, Pierce CD, Richter GT. Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations. Pediatr Blood Cancer. 2022 08; 69(8):e29733.
Score: 0.034
-
Mack JM, Frankowski S, Verkamp B, Crary SE, Spray B, Crawley L, Saccente S, Neville KA. Pupil Size and Reactivity in Pediatric Patients With Sickle Cell Disease. J Pediatr Hematol Oncol. 2023 01 01; 45(1):e44-e47.
Score: 0.033
-
Mack JM, Pierce CD, Richter GT, Spray BJ, Nicholas R, Lewis PS, Becton D, Crary SE. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography. Pediatr Blood Cancer. 2021 02; 68(2):e28824.
Score: 0.031
-
Mack JM, Verkamp B, Richter GT, Nicholas R, Stewart K, Crary SE. Effect of sirolimus on coagulopathy of slow-flow vascular malformations. Pediatr Blood Cancer. 2019 10; 66(10):e27896.
Score: 0.028
-
Mack JM, Richter GT, Crary SE. Effectiveness and Safety of Treatment with Direct Oral Anticoagulant Rivaroxaban in Patients with Slow-Flow Vascular Malformations: A Case Series. Lymphat Res Biol. 2018 06; 16(3):278-281.
Score: 0.026
-
Mack JM, Richter GT, Becton D, Salem O, Hill SEM, Crary SE. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatr Blood Cancer. 2018 06; 65(6):e27008.
Score: 0.025
-
Mack J, Mian A. Case 5: Fever and Hypoxia in a 17-year-old Boy Undergoing Cancer Chemotherapy. Pediatr Rev. 2017 May; 38(5):237.
Score: 0.024
-
Appell LE, Mack JM, Farrar JE, Roper SN, Savage MR, Pandey S, Crary SE. Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease. Pediatrics. 2024 Apr 01; 153(4).
Score: 0.010
-
Verkamp B, Zoref-Lorenz A, Francisco B, Kieser P, Mack J, Blackledge T, Brik Simon D, Yacobovich J, Jordan MB. Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis. Blood Adv. 2023 12 12; 7(23):7258-7269.
Score: 0.010
-
Dorrity J, Mack J, Wong K, Richter GT. Multimodality treatment of vascular anomalies of the head and neck. J Oral Pathol Med. 2022 Nov; 51(10):860-871.
Score: 0.009
-
Russ A, Mack J, Green-Murphy A, Occidental M, Mian A. Griscelli Type 2 Syndrome and Hemophagocytic Lymphohistiocytosis: Sisters With the Same Mutation but Different Presentations. J Pediatr Hematol Oncol. 2019 08; 41(6):473-477.
Score: 0.007
-
Estepp JH, Wiczling P, Moen J, Kang G, Mack JM, Liem R, Panepinto JA, Garg U, Kearns G, Neville KA. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure. Br J Clin Pharmacol. 2018 07; 84(7):1478-1485.
Score: 0.006
-
Raichlin E, Haglund NA, Dumitru I, Lyden ER, Johnston MD, Mack JM, Windle JR, Lowes BD. Worsening renal function in patients with acute decompensated heart failure treated with ultrafiltration: predictors and outcomes. J Card Fail. 2014 May; 20(5):376.e25-32.
Score: 0.005
-
Raichlin E, Haglund NA, Dumitru I, Lyden ER, Johnston MD, Mack JM, Windle JR, Lowes BD. Worsening renal function in patients with acute decompensated heart failure treated with ultrafiltration: predictors and outcomes. J Card Fail. 2013 Dec; 19(12):787-94.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|